Discovery of Endogenous Ouabain — A New Mammalian Hormone

  • J. M. Hamlyn


Cardiac glycosides and their aglycones have been used widely in the therapy of shock and congestive heart failure (13,23). It is generally believed that the therapeutic actions of this class of compounds are secondary to their specific interaction with a conserved receptor site on the Na+/K+-pump. Speculation that there may be an endogenous mammalian counterpart to the cardiac glycosides can be traced back more than a century and has been repeated often (26). However, most of the evidence for the existence of such a factor has been fragmentary and based primarily upon bioassay or other indirect data. Despite the fact that enormous progress has been made in the chromatographic and analytical sciences in the last thirty years, nothing was known about the general class of compounds to which this factor may belong or the manner in which this inhibitor interacts with the Na+/K+-pump. The following is an account of the purification and identification of an Na+/K+-pump inhibitor from human plasma that was carried out in collaboration with The Upjohn Company.


Cardiac Glycoside Adrenocortical Tumor Human Compound Ouabain Binding Upjohn Company 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abarquez RF (1967) Digitalis in the treatment of hypertension, a preliminary report. Acta Medica Philippina, Series 2, 3:161–170.PubMedGoogle Scholar
  2. 2.
    Baldy-Moulinier M, Arias LP, Passouant P (1973) Hippocampal epilepsy produced by ouabain. Eur Neurol 9: 333–348.PubMedCrossRefGoogle Scholar
  3. 3.
    Blanco G, Berberian G, Beauge L (1990) Detection of a highly ouabain-sensitive isoform of rat brainstem Na,K-ATPase. Biochim Biophys Acta 1027: 1–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Blaustein MP (1993) The physiological effects of endogenous ouabain: control of cell responsiveness. Am J Physiol 264: C1367–C1387.PubMedGoogle Scholar
  5. 5.
    Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS (1993) Ouabain is secreted by the adrenal gland in the awake dog. Am J Physiol 264: E413–E419.PubMedGoogle Scholar
  6. 6.
    Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM (1991) Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 17: 944–950.PubMedGoogle Scholar
  7. 7.
    Brender D, Vanhoutte PM, Shepherd JT (1969) Potentiation of adrenergic venomotor responses in dogs by cardiac glycosides. Circ Res 25: 597–606.PubMedGoogle Scholar
  8. 8.
    Caldwell RW, Songu-Mize E, Bealer SL (1985) The vasopressor response to centrally administered ouabain. Circ Res 55: 773–779.Google Scholar
  9. 9.
    Cassels BK (1985) Analysis of a Maasai arrow poison. J Ethnopharmacol 14: 273–281.PubMedCrossRefGoogle Scholar
  10. 10.
    Donaldson J, st-Pierre T, Minnich J, Barbeau A (1971) Scizures in rats associated with divalent cation inhibition of Na,K-ATPase. Can J Biochem 49: 1217–1224.PubMedCrossRefGoogle Scholar
  11. 11.
    Gillis RA, Quest JA (1980) The role of the nervous system in the cardiovascular effects of digitalis. Pharmacol Rev 31: 19–97.Google Scholar
  12. 12.
    Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM (1992) Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420–425.PubMedGoogle Scholar
  13. 13.
    Greeff K, Schadewaldt H (1981) Introduction and remarks on the history of cardiac glycosides. In: K. Greefif, ed. Cardiac Glycosides, Part I: Experimental Pharmacology. New York, Springer Verlag, p 1–12.CrossRefGoogle Scholar
  14. 14.
    Gupta JD, Harley GD (1975) Decreased adenosine triphosphatase activity in human senile cataractous lenses. Exp Eye Res 20: 207–209.PubMedCrossRefGoogle Scholar
  15. 15.
    Gutman Y, Chaimovitz M, Bergmann F, Zerachia A (1971) Hypothalamic implantation of ouabain and electrolyte secretion: evidence for a central effect on sodium balance. Physiol Behav 6: 399–401.PubMedCrossRefGoogle Scholar
  16. 16.
    Haddy FJ, Pamnani MB (1985) Evidence for a circulating endogenous Na+-K+ pump inhibitor in low renin hypertension. Fed Proc 44: 2789–27845.PubMedGoogle Scholar
  17. 17.
    Hamlyn JM (1988) Endogenous digitalis: where are we? ISI Atlas of Pharmacology 2: 339–344.Google Scholar
  18. 18.
    Hamlyn JM (1989) Increased levels of a humoral digitalis-like factor in deoxycorticosterone acetate-induced hypertension in the pig. J Endocr 122: 409–420.PubMedCrossRefGoogle Scholar
  19. 19.
    Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH (1991) Identification and characterization of a ouabainlike compound from human plasma. Proc Natl. Acad Sci (USA) 88: 6259–6263.CrossRefGoogle Scholar
  20. 20.
    Hamlyn JM, Harris DW, Ludens JH (1989) Digitalis-like activity in human plasma: purification, affinity and mechanism. J Biol. Chem 64:7395–7404.Google Scholar
  21. 21.
    Hamlyn JM, Manunta P (1992) Ouabain, Digitalis-like factors and hypertension. J. Hypertension 10(suppl 7):S99–S111.Google Scholar
  22. 22.
    Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme DW (1991) Development of an immunoassay for endogenous digitalis-like factor. Hypertension 17: 936–943.PubMedGoogle Scholar
  23. 23.
    Horton JAG, Davison MHA (1955) Ouabain in the treatment of shock. Br J Anaesth 27: 139–144.PubMedCrossRefGoogle Scholar
  24. 24.
    Huang BS, Harmsen E, Yu H, Leenen F (1992) Brain ouabain-like activity and the sympathoexcitatory and pressor effects of central sodium in rats. Circ Res 71: 1059–1066.PubMedGoogle Scholar
  25. 25.
    Jacomini LCL, Elghozi JL, Dagher G, Devynck MA, Meyer P (1984) Central hypertensive effect of ouabain in rats. Arch Int Pharmacodyn Ther 267: 310–318.PubMedGoogle Scholar
  26. 26.
    Kim RS, La Bella FS (1981) Endogenous ligands and modulators of the digitalis receptor: some candidates. Pharmacol Ther 14: 391–399.PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar R, Yankopoulos NA, Abelman WH (1973) Ouabain-induced hypertension in a patient with decompensated hypertensive heart disease. Chest 63: 105–107.PubMedCrossRefGoogle Scholar
  28. 28.
    Laredo J, Hamlyn JM (1992) Modulation of the release of endogenous ouabain from human adrenal CRL 7050 cells by peptidergic and non-peptidergic secretagogues. Endocrine Soc Abstracts, 74th Annual Meeting, San Antonio, Texas, p.71, abstr 79.Google Scholar
  29. 29.
    Ludens JH, Clark MA, DuCharme DW, Harris DW, Lutzke BS, Mandel F, Mathews WR, Sutter DM, Hamlyn JM (1991) Purification of an endogenous digitalislike factor for structural analysis. Hypertension 17: 923–929.PubMedGoogle Scholar
  30. 30.
    Ludens JH, Clark MA, Robinson FG, DuCharme DW (1992) Rat adrenal cortex is a source of circulating ouabainlike compound. Hypertension 19: 721–724.PubMedGoogle Scholar
  31. 31.
    Manunta P, Evans G, Hamilton BP, Gann D, Resau J, Hamlyn JM (1992) A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor. J. Hypertension 10(4):S27, Abstr. P36.Google Scholar
  32. 32.
    Masugi F, Ogihara T, Hasegawa T, Sakaguchi K, Kumahara Y (1988) Normalization of high plasma level of ouabain-like immunoreactivity in primary aldosteronism after removal of adrenals. J Hum Hypertens 2: 409–420.Google Scholar
  33. 33.
    Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, Ludens JH (1991) Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension 17: 930–935.PubMedGoogle Scholar
  34. 34.
    Moreth K, Renner D, Schoner W (1987) A quantitative receptor assay for digitalislike compounds in serum. Demonstration of raised concentrations in essential hypertension and correlation with arterial pressure. Klin Wochenschr 65: 179–184.PubMedCrossRefGoogle Scholar
  35. 35.
    Poston L, Sewell RB, Wilkinson SP, Richardson PJ, Williams R, Clarkson EM, MacGregor GA, de Wardener HE (1981) Evidence for a circulating sodium transport inhibitor in essential hypertension. Brit Med J 282: 847–849.CrossRefGoogle Scholar
  36. 36.
    Saxena PR, Bhargava K (1975) The importance of a central adrenergic mechanism in the cardiovascular response to ouabain. Eur J Pharmacol 31: 332–346.PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz A, Lindenmayer GE, Allen JC (1978) The sodium potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects. Pharmacol Rev 29:187–220.Google Scholar
  38. 38.
    Sekihara H, Yazaki Y, Kojima T (1992) Ouabain as an amplifier of mineralocorticoid-induced hypertension. Endocrinology 131: 3077–3082.PubMedCrossRefGoogle Scholar
  39. 39.
    Seldin R, Margolies MN, Smith TW (1974) Renal and gastrointestinal excretion of ouabain in dog and man. J. Pharmacol Exp Ther 188: 615–623.Google Scholar
  40. 40.
    Strobach H, Wirth KE, Rojsathapora K (1968) Absorption, metabolism and elimination of strophanthus glycosides in man. Naunyn-Schmiedebergs Arch Pharmacol 334: 496–500.Google Scholar
  41. 41.
    Szalay KS (1993) Ouabain — a local paracrine aldosterone synthesis regulating hormone. Life Sci 52: 1777–1780.PubMedCrossRefGoogle Scholar
  42. 42.
    Szent-Gyorgyi A. Chemical Physiology of Contraction in Body and Heart Muscle. New York, Academic Press. 1953, pp 86–91.Google Scholar
  43. 43.
    Taddei S, Salvetti A, Pedrinelli R (1988) Ouabain vasoconstricts human forearm arterioles through alpha-adrenergic stimulation. J Hypertens 6(suppl 4):S357–S359.Google Scholar
  44. 44.
    Yoda A (1974) Association and dissociation rate constant of the complexes between various cardiac monoglycosides. Ann NY Acad Sci 242: 598–616.PubMedCrossRefGoogle Scholar
  45. 45.
    Yuan C, Manunta P, Hamlyn JM, Chen S, Bohen E, Yeun J, Haddy FJ, Pamnani MB (1993) Long term ouabain administration produces hypertension in rats. Hypertension 22: 178–187.PubMedGoogle Scholar

Copyright information

© Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1994

Authors and Affiliations

  • J. M. Hamlyn
    • 1
  1. 1.Department of PhysiologyUniversity of MarylandBaltimoreUSA

Personalised recommendations